EP300 and neoplasm: In an experimental study [116], p300 inhibitors (but not anti-PD-L1 antibodies) significantly enhanced the efficacy of HDAC inhibitors on limiting tumor progression by blocking the HDAC inhibition-induced PD-L1 expression.